Adam Colborn, JD, associate vice president of congressional affairs at AMCP, shares insights on the impact of the Most Favored Nation drug pricing order when it comes to access, affordability, and innovations in US health care.

For Community Oncology, Good News in PFS Offset by Potential Wreckage of MFP Proposal

By Mary Caffrey

July 15th 2025

CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.

Graphic of a person cutting a health care price tag in half | Image credit: retrostar - stock.adobe.com

The Future of Drug Pricing: Most Favored Nation, PBMs, and Patient Access

By Laura Joszt, MA

July 11th 2025

During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.

Global health | Image credit: zephyr_p - stock.adobe.com

Trump’s Global Health Pullback Creates Leadership Opportunity for Europe

By Skylar Jeremias

July 11th 2025

The Trump administration's policies reshape global health dynamics, presenting Europe with both challenges and opportunities for leadership in health governance.

Medicaid | Image credit: Andrii - stock.adobe.com

Experts Highlight Consequences of Medicaid Rollbacks Due to Budget Bill

By Julia Bonavitacola

July 10th 2025

A webinar held by KFF on July 9 emphasized the immediate effects of the new budget bill, highlighting the impacts on Medicaid and health spending in the next decade.

...

79 80 81 82 83

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions